The Latent TB detection market is witnessing steady expansion as healthcare systems, governments, and diagnostic providers strengthen tuberculosis screening and prevention programs. The increasing prevalence of tuberculosis, growing awareness of latent infection, and government-led initiatives to improve early detection are supporting demand for reliable diagnostic solutions. Technological advancements in tuberculosis testing, particularly blood-based diagnostic methods, are also creating opportunities for market participants. According to The Insight Partners, the market encompasses tuberculin skin tests and interferon gamma release assays, with hospitals, diagnostic centers, and laboratories representing key end users.

The Latent TB Detection Market analysis indicates that the market was valued at US$ 1.23 billion in 2021 and is projected to reach US$ 2.00 billion by 2031, registering a CAGR of 5.8% during 2023–2031. The market outlook is supported by government initiatives to promote tuberculosis detection and continuing advancements in diagnostic technologies. The growing adoption of accurate and convenient testing methods across developed and emerging economies is expected to reinforce market growth throughout the forecast period.

Download Sample PDF: 

Latent TB Detection Market Overview

Latent tuberculosis infection represents an important area of disease prevention because infected individuals can potentially develop active tuberculosis. Consequently, healthcare organizations are placing greater emphasis on screening populations at elevated risk and identifying infections before disease progression. The market is therefore influenced by public health programs, screening recommendations, diagnostic accessibility, and improvements in test performance.

The market is segmented by test into tuberculin skin test and interferon gamma release assay. The interferon gamma release assay segment held the largest market share in 2023 and is anticipated to register the highest CAGR during the forecast period. These blood-based tests offer advantages in specificity and can reduce some of the practical limitations associated with traditional skin testing, supporting their adoption across healthcare settings.

By end user, the market includes hospitals, diagnostic centers, laboratories, and others. Hospitals represented the leading end-user segment in 2023 and are expected to maintain strong growth. Increasing screening activity, improved laboratory infrastructure, and greater integration of diagnostic testing into tuberculosis control programs are contributing to demand across these facilities.

Market Analysis: Key Growth Drivers

Government initiatives remain a major factor influencing the market. Countries with a high tuberculosis burden are implementing national strategies aimed at improving detection, treatment, and disease prevention. In India, for example, national tuberculosis elimination initiatives have supported access to diagnostic testing and treatment services. Similar public health programs across Asia Pacific are helping expand testing capacity and awareness.

Technological advancement is another important growth driver. Manufacturers and researchers are developing diagnostic approaches designed to provide reliable results with improved convenience and efficiency. The increasing availability of interferon gamma release assays is particularly significant because these tests provide blood-based approaches for identifying latent tuberculosis infection. The Insight Partners identifies advancements in tuberculosis diagnosis as an important opportunity for future market development.

At the same time, the market faces challenges associated with limited healthcare infrastructure, inadequate diagnostic access, awareness gaps, and tuberculosis-related stigma in some low- and middle-income countries. These factors can restrict screening rates and delay diagnosis, creating a need for affordable, accessible, and scalable testing solutions.

Competitive Landscape and Key Players

The competitive environment includes established diagnostic companies and specialized manufacturers developing testing technologies and solutions for tuberculosis detection. Key players identified by The Insight Partners include:

• QIAGEN
• BioMeriux S.A.
• F. Hoffmann La-Roche Ltd.
• BD
• ARKRAY, Inc.
• Abbott
• Serum Institute of India Pvt. Ltd
• Oxford Immunotec Ltd
• Lionex GmbH

These companies compete through product development, technological innovation, geographic expansion, strategic collaborations, and improvements in diagnostic accessibility. Recent developments, including lower-cost point-of-care testing initiatives, demonstrate the industry’s focus on expanding access to latent tuberculosis testing, particularly in high-burden markets.

Future Outlook

Continued government investment in tuberculosis elimination programs, increasing awareness of latent infection, and technological improvements in diagnostic testing are expected to support long-term demand.

The growing preference for accurate blood-based testing, particularly interferon gamma release assays, is likely to remain a significant market trend. Asia Pacific is expected to provide substantial growth opportunities as countries strengthen tuberculosis screening and prevention infrastructure. Meanwhile, manufacturers that focus on affordable, rapid, accessible, and scalable diagnostic solutions can benefit from increasing demand across high-burden regions.

Also Available in: Korean | German | Japanese | French | Chinese | Italian | Spanish

Related Reports:

Mass Spectrometry Market Size, Share & Forecast by 2034

In-vitro Diagnostics Market Share, Growth & Forecast by 2034

About Us

The Insight Partners is a one-stop provider of actionable industry research and intelligence. We help our clients get solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Healthcare IT, Manufacturing and Construction, Medical Devices, Technology, Media and Telecommunications, Food and Beverages, Consumer Goods, and Chemicals and Materials.

Contact Us

Contact Person: Ankit Mathur

Phone: +1-646-491-9876

E-mail : [email protected]